Qritive
- Industry
- Healthcare AI
- Founded Year
- 2017
- Headquarters
- Singapore
- Employee Count
- 19
Key People
- Dr. Aneesh Sathe - CEO & Co-founder
- Dr. Kaveh Taghipour - CTO & Co-founder
- Bruno Occhipinti - Chief Commercial Officer
- Encey Yao - Regulatory Manager
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The founding team comprises individuals with over a decade of experience in their respective fields.
Dr. Aneesh Sathe and Dr. Kaveh Taghipour, the co-founders, bring significant expertise in AI and healthcare, enhancing the company's credibility and potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: There is a critical need for faster and more accurate cancer diagnostics.
With increasing cancer prevalence and a shortage of pathologists, Qritive's AI solutions meet a pressing demand for efficient diagnostic tools.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has several players offering AI-based diagnostic tools.
While the market is competitive, Qritive's focus on digital pathology and strategic partnerships may provide a competitive edge.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing AI models for pathology is complex but feasible.
The integration of AI into pathology workflows involves challenges in data quality, model accuracy, and regulatory compliance, necessitating substantial resources.
- Patent
-
Aspect: Applied
Summary: The company has applied for patents but none granted yet.
Pending patents indicate a commitment to innovation and may provide competitive advantages once granted.
- Financing
-
Aspect: Well-funded
Summary: Secured $7.5M in Series A funding.
The recent funding round, led by reputable investors, provides the financial resources necessary for scaling operations and advancing product development.
- Regulatory
-
Aspect: 510k/PMA
Summary: CE certified and approved by Singapore HSA.
Achieving CE certification and HSA approval demonstrates compliance with stringent regulatory standards, facilitating market access in multiple regions.
Opportunity Rollup
- Odds of Success
- 4
- Peak Market Share
- 5.7
- Segment CAGR
- 10.7%
- Market Segment
- Digital Pathology
- Market Sub Segment
- AI-powered Diagnostic Tools
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.29 |
| 2 | 0.86 |
| 3 | 2.00 |
| 4 | 3.99 |
| 5 | 5.70 |
Key Takeaway
Qritive is well-positioned to address a critical need in cancer diagnostics with its AI-powered solutions, supported by a strong team and recent funding, though it faces challenges in a competitive and complex market.